A patent review of aldosterone synthase inhibitors (2014-present)

References

• Ferreira NS, Tostes RC, Paradis P, et al. Aldosterone, inflammation, immune system, and hypertension. Am J Hypertens. 2021 Feb 18;34(1):15–27.
   PubMed Web of Science ®Google Scholar
• Scott JH, Menouar MA, Dunn RJ. Physiology, aldosterone. Treasure Island (FL): StatPearls; 2021.
   Google Scholar
• He BJ, Anderson ME. Aldosterone and cardiovascular disease: the heart of the matter. Trends Endocrinol Metab. 2013 Jan;24(1):21–30.
   PubMed Web of Science ®Google Scholar
• Hirsch JS, Drexler Y, Bomback AS. Aldosterone blockade in chronic kidney disease. Semin Nephrol. 2014 May;34(3):307–322.
   PubMed Web of Science ®Google Scholar
• Wilczynski C, Shah L, Emanuele MA, et al. Selective hypoaldosteronism: a review. Endocr Pract. 2015 Aug;21(8):957–965.
   PubMed Web of Science ®Google Scholar
• Rajkumar V, Waseem M. Hypoaldosteronism. Treasure Island (FL): StatPearls; 2021.
   Google Scholar
• Williams JS. Evolving research in nongenomic actions of aldosterone. Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):198–203.
   PubMedGoogle Scholar
• Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014 Jul 4;(3): 965–994. DOI:https://doi.org/10.1002/cphy.c130044.
   Google Scholar
• Deinum J, Riksen NP, Lenders JW. Pharmacological treatment of aldosterone excess. Pharmacol Ther. 2015 Oct;154:120–133.
   PubMed Web of Science ®Google Scholar
• Dimitriadis K, Tsioufis C, Iliakis P, et al. Future anti-aldosterone agents. Curr Pharm Des. 2018;24(46):5548–5554.
   PubMed Web of Science ®Google Scholar
• Kallistratos MS, Pittaras A, Theodoulidis I, et al. Adverse effects of mineralocorticoid receptor antagonist administration. Curr Pharm Des. 2018;24(46):5537–5541.
   PubMed Web of Science ®Google Scholar
• Parthasarathy HK, Menard J, White WB, et al. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. J Hypertens. 2011 May;29(5):980–990.
   PubMed Web of Science ®Google Scholar
• Sueta D, Yamamoto E, Tsujita K. Mineralocorticoid receptor blockers: novel selective nonsteroidal mineralocorticoid receptor antagonists. Curr Hypertens Rep. 2020 Feb 29;22(3):21.
   PubMed Web of Science ®Google Scholar
• Duggan S. Esaxerenone: first global approval. Drugs. 2019 Mar;79(4):477–481.
   PubMed Web of Science ®Google Scholar
• Rico-Mesa JS, White A, Ahmadian-Tehrani A, et al. Mineralocorticoid receptor antagonists: a comprehensive review of finerenone. Curr Cardiol Rep. 2020 Sep 10;22(11):140.
   PubMed Web of Science ®Google Scholar
• Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020 Dec 3;383(23):2219–2229.
   PubMed Web of Science ®Google Scholar
• NDAF. 2021. Accessed 15 July 2021. Available from: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021.
   Google Scholar
• Mihailidou AS, Tzakos AG, Ashton AW. Non-genomic effects of aldosterone. Vitam Horm. 2019;109:133–149.
   PubMed Web of Science ®Google Scholar
• Feldman RD, Limbird LE. GPER (GPR30): a nongenomic receptor (GPCR) for steroid hormones with implications for cardiovascular disease and cancer. Annu Rev Pharmacol Toxicol. 2017 Jan 6;57(1):567–584.
   PubMed Web of Science ®Google Scholar
• Kolodziejczyk P, Gromotowicz-Poplawska A, Aleksiejczuk M, et al. New sides of aldosterone action in cardiovascular system as potential targets for therapeutic intervention. Curr Drug Targets. 2018;19(16):1968–1979.
   PubMed Web of Science ®Google Scholar
• Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev. 2005 Jan;10(1):7–13.
   PubMed Web of Science ®Google Scholar
• Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant. 2013 Jan;28(1):36–43.
   PubMed Web of Science ®Google Scholar
• Lea WB, Kwak ES, Luther JM, et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 2009 May;75(9):936–944.
   PubMed Web of Science ®Google Scholar
• Fiebeler A, Nussberger J, Shagdarsuren E, et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005 Jun 14;111(23):3087–3094.
   PubMed Web of Science ®Google Scholar
• Lenzini L, Zanotti G, Bonchio M, et al. Aldosterone synthase inhibitors for cardiovascular diseases: a comprehensive review of preclinical, clinical and in silico data. Pharmacol Res. 2021 Jan;163:105332.
   PubMed Web of Science ®Google Scholar
• Cerny MA. Progress towards clinically useful aldosterone synthase inhibitors. Curr Top Med Chem. 2013;13(12):1385–1401.
   PubMed Web of Science ®Google Scholar
• Weldon SM, Brown NF. Inhibitors of aldosterone synthase. Vitam Horm. 2019;109:211–239.
   PubMed Web of Science ®Google Scholar
• Aragao-Santiago L, Gomez-Sanchez CE, Mulatero P, et al. Mouse models of primary aldosteronism: from physiology to pathophysiology. Endocrinology. 2017 Dec 1;158(12):4129–4138.
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Mitsuuchi Y, Toda K, et al. Cloning of cDNA and genomic DNA for human cytochrome P-45011 beta. FEBS Lett. 1990 Sep 3;269(2):345–349.
   PubMed Web of Science ®Google Scholar
• Bernhardt R. The potential of targeting CYP11B. Expert Opin Ther Targets. 2016 Aug;20(8):923–934.
   PubMed Web of Science ®Google Scholar
• Menard J, Pascoe L. Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition? J Hypertens. 2006 Jun;24(6):993–997.
   PubMed Web of Science ®Google Scholar
• Amar L, Azizi M, Menard J, et al. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010 Nov;56(5):831–838.
   PubMed Web of Science ®Google Scholar
• Wang HZ, Tian JB, Yang KH. Efficacy and safety of LCI699 for hypertension: a meta-analysis of randomized controlled trials and systematic review. Eur Rev Med Pharmacol Sci. 2015;19(2):296–304.
   PubMed Web of Science ®Google Scholar
• Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab. 2014 Apr;99(4):1375–1383.
   PubMed Web of Science ®Google Scholar
• Papillon J. LFF269: a cortisol-sparing CYP11B2 inhibitor that lowers aldosterone in human subjects. 254th ACS National Meeting, Washington, DC, USA. 2017 Aug;MEDI-222.
   Google Scholar
• Bogman K, Schwab D, Delporte ML, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017 Jan;69(1):189–196.
   PubMed Web of Science ®Google Scholar
• Sloan-Lancaster J, Raddad E, Flynt A, et al. LY3045697: results from two randomized clinical trials of a novel inhibitor of aldosterone synthase. J Renin Angiotensin Aldosterone Syst. 2017;18(3):1470320317717883.
   Web of Science ®Google Scholar
• Hu Q, Yin L, Hartmann RW. Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases. J Med Chem. 2014 Jun 26;57(12):5011–5022.
   PubMed Web of Science ®Google Scholar
• Balestra M, Burke J, Chen Z, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Naphthyridines, azaindoles and related compounds as aldosterone synthase inhibitors and their preparation patent. US20140323468. 2014.
   Google Scholar
• Weldon SM, Cerny MA, Gueneva-Boucheva K, et al. Selectivity of BI 689648, a novel, highly selective aldosterone synthase inhibitor: comparison with FAD286 and LCI699 in nonhuman primates. J Pharmacol Exp Ther. 2016;359(1):142–150.
   PubMed Web of Science ®Google Scholar
• Hornberger KR, Meyers KM, Nemoto PA, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Preparation of heteroaryl compounds as aldosterone synthase inhibitors patent. WO2016061161. 2016.
   Google Scholar
• Chen Z, Cogan D, Guo X, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Preparation of pyranopyridine as aldosterone synthase inhibitors patent. WO2016089800. 2016.
   Google Scholar
• Burke J, Cogan D, Lord J, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Pyranoimidazolones as aldosterone synthase inhibitors and their preparation patent. WO2016014736. 2016.
   Google Scholar
• Balestra M, Bentzien JM, Burke J, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Preparation of fused isoxazole compounds as aldosterone synthase inhibitors and therapeutic uses thereof patent. WO2016123275. 2016.
   Google Scholar
• McKibben BP, Meyers KM, Zhang Y, et al., inventors; Boehringer Ingelheim International GmbH, assignee. Preparation of bicyclic imidazole derivatives as selective aldosterone synthase inhibitors useful for treatment of renal disease, cardiovascular diseases and fibrotic disorders patent. WO2018005177. 2018.
   Google Scholar
• Meyers K, Cogan DA, Burke J, et al. Dihydrobenzisoxazole-4-one compounds are novel selective inhibitors of aldosterone synthase (CYP11B2) with in vivo activity. Bioorg Med Chem Lett. 2018;28(5):979–984.
   PubMed Web of Science ®Google Scholar
• Hoyt SB, Park MK, London C, et al., inventors; Merck Sharp & Dohme Corp., assignee. Preparation of benzimidazole derivatives as aldosterone synthase inhibitors patent. WO2012012478. 2012.
   Google Scholar
• Hoyt SB, Park MK, London C, et al. Discovery of benzimidazole CYP11B2 inhibitors with in vivo activity in rhesus monkeys. ACS Med Chem Lett. 2015;6(5):573–578.
   PubMed Web of Science ®Google Scholar
• Hoyt SB, Petrilli WL, London C, et al., inventors; Merck Sharp & Dohme Corp. ElexoPharm GmbH, assignee. Triazoloquinoline derivatives as aldosterone synthase inhibitors and their preparation patent. WO2012148808. 2012.
   Google Scholar
• Bennett DJ, Cai J, Carswell E, et al., inventors; Merck Sharp & Dohme Corp., assignee. Preparation of pyrazolopyridine compounds as aldosterone synthase inhibitors patent. WO2013043521. 2013.
   Google Scholar
• Bennett DJ, Cai J, Carswell E, et al., inventors; Merck Sharp & Dohme Corp., assignee. Pyrazolopyridyl compounds as aldosterone synthase inhibitors patent. US20140288094. 2014.
   Google Scholar
• Bennett DJ, Cai J, Carswell E, et al., inventors; Merck Sharp & Dohme Corp., assignee. Preparation of triazolopyridine compounds as aldosterone synthase inhibitors patent. WO2013043520. 2013.
   Google Scholar
• Bennett DJ, Cai J, Carswell E, et al., inventors; Merck Sharp & Dohme Corp. Jubilant Organosys Limited, assignee. Triazolopyridyl compounds as aldosterone synthase inhibitors patent. US20140228396. 2014.
   Google Scholar
• Ali A, Bennett DJ, Cai J, et al., inventors; Merck Sharp & Dohme Corp., assignee. Imidazopyridyl compounds as aldosterone synthase inhibitors patent. WO2013043518. 2013.
   Google Scholar
• Ali A, Bennett DJ, Cai J, et al., inventors; Merck Sharp & Dohme Corp., assignee. Imidazopyridyl compounds as aldosterone synthase inhibitors patent. US9173873. 2015.
   Google Scholar
• Ali A, Lo MM-C, Metzger E, et al., inventors; Merck Sharp & Dohme Corp. ElexoPharm GmbH, assignee. Indoline compounds as aldosterone synthase inhibitors related applications patent. WO2014055595. 2014.
   Google Scholar
• Hoyt SB, Taylor JA, London C, et al., inventors; Merck Sharp & Dohme Corp., assignee. Indazole compounds as aldosterone synthase inhibitors patent. WO2014099833. 2014.
   Google Scholar
• Hoyt SB, Taylor J, London C, et al. Discovery of indazole aldosterone synthase (CYP11B2) inhibitors as potential treatments for hypertension. Bioorg Med Chem Lett. 2017;27(11):2384–2388.
   PubMed Web of Science ®Google Scholar
• Whitehead BR, Lo MM, Ali A, et al. Imidazopyridyl compounds as aldosterone synthase inhibitors. Bioorg Med Chem Lett. 2017 Jan 15;27(2):143–146.
   PubMed Web of Science ®Google Scholar
• Ali A, Bey E, Hartmann R, et al., inventors; Merck Sharp & Dohme Corp. ElexoPharm GmbH, assignee. Tricyclic triazole aldosterone synthase inhibitors and their therapeutic use patent. WO2013151876. 2013.
   Google Scholar
• Ali A, Bey E, Hartmann R, et al., inventors; Merck Sharp & Dohme Corp. Elexopharm GmbH, assignee. Aldosterone synthase inhibitors patent. US20150306091. 2015.
   Google Scholar
• Hu Q, Yin L, Ali A, et al. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability. J Med Chem. 2015 Mar 12;58(5):2530–2537.
   PubMed Web of Science ®Google Scholar
• Hoyt SB, Petrilli W, London C, et al. Discovery of triazole CYP11B2 inhibitors with in vivo activity in rhesus monkeys. ACS Med Chem Lett. 2015;6(8):861–865.
   PubMed Web of Science ®Google Scholar
• Petrilli WL, Hoyt SB, London C, et al. Discovery of spirocyclic aldosterone synthase inhibitors as potential treatments for resistant hypertension. ACS Med Chem Lett. 2017;8(1):128–132.
   PubMed Web of Science ®Google Scholar
• Ushirogochi H, Sasaki W, Onda Y, et al., inventors; Mitsubishi Tanabe Pharma Corporation, assignee. Disubstituted 1,2,4-triazine compound and its use for pharmaceutical composition and method for prevention or treatment of diseases or symptoms involving aldosterone patent. WO2015163427. 2015.
   Google Scholar
• Sakakibara R, Ushirogochi H, Sasaki W, et al., inventors; Mitsubishi Tanabe Pharma Corporation, assignee. Preparation of nitrogen-containing aromatic heterocyclic compounds having inhibitory activity on aldosterone synthase patent. WO2017069226. 2017.
   Google Scholar
• Sakakibara R, Sasaki W, Yamaguchi M, et al., inventors; Mitsubishi Tanabe Pharma Corporation, assignee. Preparation of nitrogen-containing heterocyclic compounds as aldosterone synthase inhibitors patent. WO2017170765. 2017.
   Google Scholar
• Sakakibara R, Sasaki W, Onda Y, et al. Discovery of novel pyrazole-based selective aldosterone synthase (CYP11B2) inhibitors: a new template to coordinate the heme-iron motif of CYP11B2. J Med Chem. 2018;61(13):5594–5608.
   PubMed Web of Science ®Google Scholar
• Ksander GM, Meredith E, Monovich LG, et al., inventors; Novartis A.-G. Novartis Pharma G.m.b.H., assignee. Preparation of condensed imidazole derivatives for the inhibition of aldosterone synthase and aromatase patent. WO2007024945. 2007.
   Google Scholar
• Papillon J, Ksander GM, Hu Q-Y, inventors; Novartis A.-G. Novartis Pharma G.m.b.H., assignee. Preparation of tetrahydroimidazo[1,5-a]pyrazine derivatives as aldosterone synthase and/or 11β-hydroxylase inhibitors patent. WO2007139992. 2007.
   Google Scholar
• Hu Q-Y, Ksander GM, inventors; Novartis AG, assignee. Preparation of 4-imidazolyl-1,2,3,4-tetrahydroquinoline derivatives as aldosterone/11β-hydroxylase inhibitors patent. WO2008076860. 2008.
   Google Scholar
• Adams C, Hu Q-Y, McGuire LW, et al., inventors; Novartis AG, assignee. Preparation of pyridinylindole derivatives for use as aldosterone synthase modulators patent. WO2009156462. 2009.
   Google Scholar
• Chamoin S, Hu Q-Y, Papillon J, inventors; Novartis AG, assignee. Preparation of aryl pyridine as aldosterone synthase inhibitors patent. WO2010130796. 2010.
   Google Scholar
• Adams CM, Chamoin S, Hu Q-Y, inventors; Novartis AG, assignee. Preparation of 5-(pyridin-3-yl)-1,3-dihydroindol-2-one derivatives as modulators of aldosterone synthase and/or CYP11B1 patent. WO2010130794. 2010.
   Google Scholar
• Herold P, Mah R, Tschinke V, et al., inventors; Novartis AG Speedel Experimenta AG, assignee. Heterocyclic spiro-compounds as aldosterone synthase inhibitors patent. US8071774. 2011.
   Google Scholar
• Meredith EL, Ksander G, Monovich LG, et al. Discovery and in vivo evaluation of potent dual CYP11B2 (aldosterone synthase) and CYP11B1 inhibitors. ACS Med Chem Lett. 2013;4(12):1203–1207.
   PubMed Web of Science ®Google Scholar
• Papillon JPN, Adams CM, Hu Q-Y, et al. Structure-activity relationships, pharmacokinetics, and in vivo activity of CYP11B2 and CYP11B1 inhibitors. J Med Chem. 2015;58(11):4749–4770.
   PubMed Web of Science ®Google Scholar
• Papillon JPN, Lou C, Singh AK, et al. Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a cortisol-sparing CYP11B2 inhibitor that lowers aldosterone in human subjects. J Med Chem. 2015;58(23):9382–9394.
   PubMed Web of Science ®Google Scholar
• Aebi J, Amrein K, Hornsperger B, et al., inventors; Hoffmann-La Roche Inc., assignee. Preparation of phenyl-tetrahydroisoquinoline derivatives useful in the treatment of disease patent. US20130274287. 2013.
   Google Scholar
• Martin RE, Aebi JD, Hornsperger B, et al. Discovery of 4-aryl-5,6,7,8-tetrahydroisoquinolines as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors: in vivo evaluation in rodents and cynomolgus monkeys. J Med Chem. 2015;58(20):8054–8065.
   PubMed Web of Science ®Google Scholar
• Aebi J, Amrein K, Britton R, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of phenyldihydropyridine derivatives for use as aldosterone synthase inhibitors patent. WO2015055602. 2015.
   Google Scholar
• Martin RE, Lehmann J, Alzieu T, et al. Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2). Org Biomol Chem. 2016;14(25):5922–5927.
   PubMed Web of Science ®Google Scholar
• Aebi J, Amrein K, Fantasia SM, et al., inventors; F. Hoffmann-La Roche AG, assignee. Preparation of bicyclic dihydroquinoline-2-one derivatives as CYP11B2 and CYP11B1 inhibitors for therapy patent. WO2013041591. 2013.
   Google Scholar
• Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG, assignee. Preparation of dihydroquinolinone derivatives for use as CYP11B2 or CYP11B1 inhibitors patent. WO2013037779. 2013.
   Google Scholar
• Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of dihydroquinoline-2-one derivatives that are aldosterone synthase inhibitors useful in therapy and prophylaxis of primary aldosteronism, cushing syndrome and other diseases patent. WO2014139981. 2014.
   Google Scholar
• Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of dihydroquinolin-2-one derivatives as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors patent. WO2014135561. 2014.
   Google Scholar
• Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of pyrazolyl dihydroquinolinones as aldosterone synthase inhibitors useful in therapy patent. WO2016066662. 2016.
   Google Scholar
• Aebi J, Amrein K, Hornsperger B, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of pyrazolyl-3,4-dihydroquinolin-2-one as aldosterone synthase inhibitors useful in therapy patent. WO2016066663. 2016.
   Google Scholar
• Aebi J, Amrein K, Chen W, et al., inventors; F. Hoffmann-La Roche AG, assignee. New bicyclic dihydroisoquinolin-1-one derivatives as aldosterone synthase inhibitors and their preparation patent. WO2013079452. 2013.
   Google Scholar
• Aebi J, Amrein K, Chen W, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of new 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydroisoindol-1-one compounds as aldosterone synthase inhibitors patent. WO2014191336. 2014.
   Google Scholar
• Aebi J, Amrein K, Chen W, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of new 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydroisoindol-1-one compounds as aldosterone synthase inhibitors patent WO2014191338. 2014.
   Google Scholar
• Aebi J, Amrein K, Chen W, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of new 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydroisoindol-1-one compounds as aldosterone synthase inhibitors patent. WO2014191340. 2014.
   Google Scholar
• Aebi J, Amrein KE, Chen J, et al., inventors; F. Hoffmann-La Roche AG Hoffmann-La Roche Inc., assignee. Preparation of spirodiamine derivatives as aldosterone synthase inhibitors patent. WO2016055394. 2016.
   Google Scholar
• Liu Y, Wu J, Zhou M, et al. Discovery of 3-pyridyl isoindolin-1-one derivatives as potent, selective, and orally active aldosterone synthase (CYP11B2) inhibitors. J Med Chem. 2020;63(13):6876–6897.
   PubMed Web of Science ®Google Scholar
• Sparks S, Yates CM, Shaver SR, et al., inventors; Viamet Pharmaceuticals (Bermuda), Ltd., assignee. Preparation of pyridazinyl benzimidazoles and related nitrogen heterocycles as metalloenzyme inhibitors for the treatment of diseases patent. WO2018125800. 2018.
   Google Scholar
• Sparks S, Yates CM, Shaver SR, inventors; Viamet Pharmaceuticals (Bermuda), Ltd., assignee. Preparation of pyrimidinyl benzimidazoles and related nitrogen heterocycles as metalloenzyme inhibitors for the treatment of diseases patent. WO2018125799. 2018.
   Google Scholar
• Sparks SM, Danger DP, Hoekstra WJ, et al. Development of highly selective pyrimidine-based aldosterone synthase (CYP11B2) inhibitors. ACS Med Chem Lett. 2019 Jul 11;10(7):1056–1060.
   PubMed Web of Science ®Google Scholar
• Panicker B, Oehlen LJWM, inventors; Angion Biomedica Corp, assignee. Preparation of benzothiazolyl pyridyl alkanols for reducing aldosterone patent. WO2016109492. 2016.
   Google Scholar
• Kliuchenovich AV, Strushkevich NV, Gilep AA, inventors; Obshchestvo s Ogranichennoi Otvetstvennostiu “Target Medikals,” assignee. Aldosterone synthase inhibitors based on 2-amino-4h-pyran-3-carbonitrile derivatives patent. RU2717310. 2020.
   Google Scholar
• Strushkevich N, Gilep AA, Shen L, et al. Structural insights into aldosterone synthase substrate specificity and targeted inhibition. Mol Endocrinol. 2013;27(2):315–324.
   PubMedGoogle Scholar
• Brixius-Anderko S, Scott EE. Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design. J Biol Chem. 2019 Jan 11;294(2):453–460.
   PubMed Web of Science ®Google Scholar
• Frimodt-Moller M, Persson F, Rossing P. Mitigating risk of aldosterone in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2020 Jan;29(1):145–151.
   PubMed Web of Science ®Google Scholar